Inge Dierynck
Tibotec
20 Papers
157 Citations
Inge Dierynck is an academic researcher from Tibotec. The author has contributed to research in topics: Darunavir & Lopinavir. The author has an hindex of 12, co-authored 20 publications.
Chat about Author
Papers
Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.
Stéphane Blanche,Rosa Bologna,Pedro Cahn,Sorin Rugină,Patricia M. Flynn,Claudia Fortuny,Peter Vis,Vanitha Sekar,Ben van Baelen,Inge Dierynck,Sabrina Spinosa-Guzman +10 more
TL;DR: In treatment-experienced children and adolescents, DRV/r showed comparable exposure to adults with appropriate dose selection, favorable safety and tolerability, improved body weight and significant virologic response.
49
Crystal Structure of Lysine Sulfonamide Inhibitor Reveals the Displacement of the Conserved Flap Water Molecule in Human Immunodeficiency Virus Type 1 Protease
TL;DR: The crystal structure of a lysine sulfonamide binds to the active site of HIV-1 protease in a novel manner, displacing the conserved water and making extensive hydrogen bonds with every region of the active sites.
Patent
Methods of assessing HIV integrase inhibitor therapy
Johan Vingerhoets,Lieve Emma Jan Michiels,Inge Dierynck +2 more
- 08 Aug 2002
TL;DR: In this article, the authors present methods and products for the evaluation of HIV treatment based on evaluating molecular events at the HIV integrase resulting in altered therapeutic efficacy of the investigated compounds.
33
The Impact of Individual Human Immunodeficiency Virus Type 1 Protease Mutations on Drug Susceptibility Is Highly Influenced by Complex Interactions with the Background Protease Sequence
H. Van Marck,Inge Dierynck,Guenter Kraus,Sabine Hallenberger,T. Pattery,G. Muyldermans,L. Geeraert,L. Borozdina,Rachelle Bonesteel,C. Aston,E. Shaw,Q. Chen,C. Martinez,V. Koka,J. Lee,E. Chi,MP de Béthune,Kurt Hertogs +17 more
TL;DR: The novel bioinformatics resistance determination approach presented here elaborates on patient data and demonstrates how the specific mutational background greatly influences the impact of individual mutations on PI susceptibility in clinical patterns.
19
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Inge Dierynck,Sandra De Meyer,Erkki Lathouwers,Carline Vanden Abeele,Tom Van De Casteele,Sabrina Spinosa-Guzman,Marie-Pierre de Béthune,Gaston Picchio +7 more
TL;DR: In vitro susceptibility to DRV was comparable across HIV-1 subtypes in a broad panel of primary isolates and in recombinant clinical isolates, confirming their broad anti-HIV-1 activity.
18